Tradepoint Atlantic plans $100M logistics complex in Howard County
Tradepoint Atlantic's expansion into Howard County signals a new chapter for the developer, with local officials hailing the project as transformative for the area.
Story Highlights Tradepoint Atlantic is planning a $100 million logistics complex in Howard County.
The project will create 500 new jobs in the Savage area.
Groundbreaking for the first warehouse begins in early 2026.
Tradepoint Atlantic will expand its footprint in Maryland with a $100 million, 500,000-square-foot logistics complex in Howard County.
Plans for Tradepoint at Savage Crossing, located on Route 1 near Laurel, were released Tuesday by Howard County officials and the developer. The project represents Tradepoint's first Maryland development outside of Baltimore County, where the firm has converted 3,300 acres at the former Bethlehem Steel plant in Dundalk into an international trade center with over $2 billion in private investment so far. About 500 new jobs are expected in Savage when the 35-acre project is built out.
The Baltimore County site hit its 10-year anniversary last year, and Tradepoint officials said it's time for more growth in the region. The move into Howard County is the result of ongoing negotiations with state and county leaders to develop the state-of-the-art industrial and possible manufacturing complex at 9299 Washington Blvd.
DOWNLOAD the free BBJ app for breaking news alerts on your phone.
Christiana Rigby, a member of the County Council whose district includes Savage, called the move transformative for the southern Howard County community between Jessup and Laurel that today is a mix of vacant and dilapidated structures, small hotels and newly developed multi-family complexes.
"Bringing $100 million to revitalize our portion of the Route 1 corridor and creating hundreds of new jobs — I'm thrilled," Rigby said.
The future Tradepoint expansion property today holds WillScot, a mini-storage and portable office container firm, which is expected to sell the site to the large developer by year's end for an undisclosed price. Groundbreaking on the first of three Class A industrial warehouses will take place in early 2026, and the complex is expected to be completed in 2029.
"Our hope is that successful development like Tradepoint at Savage Crossing will add to the economic development ecosystem here and further encourage other businesses to look to this area for their next expansion," Howard County Executive Calvin Ball said.
Howard County recently paved the way for the expansion by passing new land use regulations to allow flex warehouse development on Route 1. A portion of the large suburban county was also recently awarded a state Enterprise Zone designation, which includes part of Route 1 near Savage, but not the Tradpoint expansion site, Ball added. That designation will allow tax breaks and other incentives to businesses located within those boundaries, and Ball pledged the county's support over the coming years to help Tradepoint put down roots.
"We realize that Tradepoint Atlantic is making a significant investment at a challenging time. Please know that we will remain your partner through this journey. Together we will meet the magic of this moment," Ball said.
Aaron Tomarchio, senior vice president at Tradepoint, said the move to expand into a new county was a way to "build upon the development model we had created." He noted that Savage's location between Baltimore and Washington, D.C. and proximity to Interstate 95 were major drivers for the project.
"Our team set their eyes on other opportunities where we could bring thoughtful, redevelopment strategies and transformational change to a new project and community," Tomarchio said.
Marc Salotti, Tradepoint's managing director, said the firm could grow further in other jurisdictions with locations "to be determined."
expand
A bird's eye view of the 3,300-acre Tradepoint Atlantic development in Sparrow's Point.
Tradepoint Atlantic
State Sen. Guy Guzzone, who represents a portion of the Route 1 corridor, said the area has been cited for years as ripe for redevelopment and upgrades. The thoroughfare runs through Maryland as an alternate route to Interstate 95, and was once the only roadway stretching from Maine to Florida, before the U.S. interstate system was built.
"This is a big one to have (Tradepoint) come here to redevelop this land," Guzzone said. "The fundamental of all this is jobs. At the basis, we're trying to build a community where people have jobs close to where they live and have economic development that lifts up the community. We're so lucky."
The private Tradepoint development is fueled by investors at Redwood Holdings, chaired by the low-profile yet powerhouse Baltimore investor Jim Davis. Redwood joined with Hilco Global in 2014 to acquire Sparrows Point out of bankruptcy before Hilco sold its share in the project.
Today, Tradepoint at Sparrows Point has more than 13,000 workers and other officials on site each day, and just over 50 warehouse, logistics and manufacturing facilities. A massive private port is under development on 330 acres, and the Sparrows Point Container Terminal is expected to be completed by early 2028, with 1,000 new jobs expected to follow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
4 days ago
- San Francisco Chronicle
A new California winery will change your mind about Chardonnay
It's become fashionable in recent years to praise lean, laser-focused California Chardonnay — some would say 'Chablis-style' Chardonnay — as a rebuke to the overblown butter-and-oak bombs that proliferated beginning in the 1990s. But that line of thinking neglects to account for the full-bodied California Chardonnays that are made well — expertly, even. When a winemaker gets it right, there's nothing like it. A rich Chardonnay can be as luscious as uni melting on the tongue, as decadent as a smear of soft-ripened cheese, as satisfying as biting into a juicy, runny peach. A new Sonoma County winery, Sphaerics, makes a convincing argument for this style. It produces Chardonnay exclusively, and all three of its single-vineyard wines are rich and complex, with a tense line of acidity that keeps them in balance. Now, three years in, Sphaerics will expand its small production thanks to the purchase of its own Sonoma Coast vineyard. Since meeting as students at U.C. Davis, Laura Jones and Brian Ball had always wanted to start their own winery, said Ball, 'but only if we can make something really unbelievable.' The couple have each had varied careers in the wine industry and now both work at Skipstone Ranch in Alexander Valley; he's the general manager, she's the winemaker. They set their sights on Chardonnay, not only because it's what they love to drink but also because Jones loves making it. Jones spent five years as the assistant winemaker at Aubert Wines in Calistoga, arguably the benchmark producer of rich, creamy, indulgent California Chardonnay. (Conveniently, Skipstone's only white wine is a Viognier, so there's no competition with their employer.) Their opportunity arrived in 2022, when the Jackson family offered to sell them Chardonnay grapes from the Upper Barn Vineyard, one of Skipstone's neighbors in Alexander Valley. Upper Barn has a notable legacy with some of the most prestigious names of the rich-Chardonnay camp: Helen Turley made Upper Barn Chardonnay when she was the winemaker for Peter Michael Winery, where it became a bottling known as Mon Plaisir, 'my pleasure.' She also used Upper Barn grapes for her own label, Marcassin. Turley's protégé Mark Aubert later made the Upper Barn Chardonnay when he worked for Peter Michael. Now Aubert's protégé, Jones, would be the next steward of these grapes. 'It was like this mentor-to-protégé winemaker family tree,' Ball said. They call the Upper Barn Chardonnay 'If and Only If,' a reference to their condition for starting the winery in the first place. The 2023 vintage is very expressive, reminding me of marzipan, ginger and apricot. As creamy and full as it is, it has a persistent, refreshing brightness. 'I love really long fermentations,' said Jones. She ferments her Chardonnays in barrels using indigenous yeast, and they typically don't complete their secondary malolactic fermentations until the following spring. (Most wineries would have this wrapped up within a matter of weeks following harvest.) She doesn't filter or fine the wines, nor does she practice battonage — the stirring of lees while a wine is aging in barrel, which can add oomph and body — meaning the wine gets its richness primarily from its raw materials. 'I pick on the riper side,' said Jones. 'The grapes should taste delicious. They should taste good. Like candy.' This sounds like an almost direct refutation of winemaker Raj Parr 's anti-ripeness maxim, now famous in industry circles: 'If you pick a grape off the vine and it tastes yummy, you've already missed it.' The Upper Barn Chardonnay is Sphaerics' flagship, and its most expensive at $140. The rest of the lineup consists of Overline ($65), a lighter expression from Carneros that's reminiscent of tangy yogurt, yellow peach and basil; and On Days and Nights ($80), from the Russian River Valley, which has flavors of fennel, toasted hazelnut and Meyer lemon. These are bold prices for Chardonnay, in line with high-end producers like Aubert, Peter Michael and Kistler. This year, Ball and Jones will add red wine to the mix after acquiring their estate vineyard. Located near the town of Occidental, the site has 13 acres of Pinot Noir and Chardonnay. When the couple began scouting for properties, Ball pulled up Google Maps and asked Jones: 'Where in your dream would you want our vineyard to be?' She pointed to this particular area of the Sonoma Coast, where the fluffy Goldridge soils are known to be ideal for Burgundian grape varieties. Many of the wines that Jones had made at Aubert came from this area. When they saw a listing in that exact neighborhood that fit their budget, they felt that it was fate. They closed in May — and are legally prohibited from naming the vineyard's previous owner or which wineries bought its fruit. Coming up with a name for a winery that's not already trademarked is notoriously difficult, especially when 'your last names are not exciting,' said Jones. They chose Sphaerics, the title of the foundational text on the geometry of the sphere written by Theodosius of Bithynia in the 2nd or 1st century BC. It's partly a play on Ball's last name. It's also a nod to the shape of winemaking itself. 'Think of the most important objects that make wine,' Ball said: 'the shape of a grape, the shape of the earth, the shape of the moon.'
Associated Press
5 days ago
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
6 days ago
- Yahoo
DeMar DeRozan gets 100% real on playing with Lonzo Ball
The post DeMar DeRozan gets 100% real on playing with Lonzo Ball appeared first on ClutchPoints. DeMar DeRozan recently opened up about playing with Lonzo Ball on the Chicago Bulls. DeRozan played with the Bulls for three seasons from 2021 to 2024 and came to Chicago at the same time as Lonzo Ball in 2021. The issue is that Ball was dealing with injuries during most of his time in Chicago while DeRozan was his teammate. Advertisement To this point, Ball has missed most of his time playing with the Bulls. He played for the first time in October 2024 since 2022. Ball and DeRozan barely played basketball together, but when they did, things came together easily, helping the offense flow much better than it did without him. On a recent Run Your Race Podcast episode with Theo Pinson and AJ Richardson, DeRozan spoke about what it was like playing with Ball and how easy everything was. He said, 'When you talk about a piece missing for something… Lonzo was that big piece of the puzzle that put everything together for all of us. He made everything so easy.' Ball's size is what makes him stand out as a point guard. At 6-foot-7 and 190 pounds, there are not many point guards like him, and that's why he presents such a matchup issue when he is healthy and able to play. The one season he was able to play with DeRozan on the Bulls, Ball had a 2.2 assist-to-turnover ratio, and he averaged 5.1 assists per game during that season. The combination of DeRozan and Ball never got a lot of time together with the Bulls due to his injuries, and before Ball was able to come back from injury, DeRozan was traded to the Sacramento Kings in a sign-and-trade that also involved the San Antonio Spurs in a three-team deal. Advertisement Hearing DeRozan praise playing with Ball and how much he enjoyed it shows that it was a case of what could have been. Ball could have developed into an All-Star-level talent if it weren't for some of the injuries he has suffered in his career. Both players still play well with DeRozan in Sacramento and Ball back in Chicago, but those years with the Bulls will be filled with missed opportunities.
